Competing amicus briefs filed in Supreme Court transgender sports cases include 207 Republican state lawmakers and 130 ...

If you are wondering whether Amicus Therapeutics at around US$14.28 is offering good value right now, this article walks ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best NASDAQ stocks to buy in 2026. On December 22, H.C. Wainwright ...

BioMarin adds scale of operations, including global commercial footprint and in-house manufacturing capabilities for rare ...

Amicus Therapeutics (FOLD) has been drawing fresh attention after a strong recent share move, with the stock up about 46% over the past month and roughly 72% in the past 3 months. See our latest ...

The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially supporting the company’s revenue stream.

The termination of the merger with the special purpose acquisition company, ARYA Sciences Acquisition Corp IV, means that Amicus now needs to save $400 million—the same amount that the gene therapy ...

The Labor Department has withdrawn its previous support of plaintiffs in a case concerning the burden of proof involving a university 403(b) plan.

Amicus has endured a tough few years of pipeline flops and a roller coaster stock ride, but now it’s riding the special purpose acquisition company wave, spinning off its gene therapy unit in a $600 ...

Amicus Therapeutics’ plan to spin off its gene therapy assets has run into the reality of the biotech stock market in 2022. With “market conditions” sinking the planned special purpose acquisition ...

Forbes contributors publish independent expert analyses and insights. I study high performers in sports for lessons in business leadership. Nov 12, 2021, 12:31pm EST Nov 12, 2021, 12:31pm EST This ...